Skip to main content
Back
Watch Compare

FILANA THERAPEUTICS, INC.

Data quality: 83%
FLNA
NASDAQ Manufacturing Chemicals
$1.64
▼ $0.08 (-4.65%)
Mkt Cap: 83.09 M
Price
$1.72
Mkt Cap
83.09 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -32.83 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-107.32%
Below sector avg (-53.58%)
ROIC-88.79%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio2.27
Interest CoverageN/A

Valuation

PE (TTM)
-0.91
Above sector avg (-1.48)
P/B Ratio1.02
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1366 peers)
Metric Stock Sector Median
P/E -0.9 -1.5
P/B 1.0 1.6
ROE % -107.3 -53.6
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

1 analyst
Buy
Current
$1.64
+387.8%
Target
$8.00
$8.00
$8.00
$8.00
Forecast
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 — 0.0 —
FY2026 -$1.02
-$1.02 – -$1.02
 0.0 1

Earnings Surprises

Last 3 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.30 -$0.26 +13.3%
Q32025 -$0.27 -$0.22 +18.5%
Q22025 N/A -$0.92 —

Dividend History

2 yr streak
Ex-Date Payment Date Amount Yield
Dec 13, 2012 — $5.25 N/A
Dec 13, 2010 — $14.00 N/A

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -90.97 M
ROE -107.32% ROA -68.63%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -32.83 M
ROIC -88.79% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.27
Interest Coverage N/A Asset Turnover N/A
Working Capital 60.86 M Tangible Book Value 81.57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 2 yrs
Valuation
P/E Ratio -0.91 Forward P/E N/A
P/B Ratio 1.02 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -39.52%
Market Cap 83.09 M Enterprise Value -22.99 M
Per Share
EPS (Diluted TTM) -1.88 Revenue / Share N/A
FCF / Share -0.68 OCF / Share -0.67
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 36.09%
SBC-Adj. FCF -52.65 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -90.97 M -24.34 M -97.22 M -76.25 M -32.39 M
EPS (Diluted) -1.88 -1.46 — — —
Gross Profit — — — — —
Operating Income -95.39 M -141.45 M -105.96 M -80.02 M -32.87 M
EBITDA — — — — —
R&D Expenses 26.59 M 69.64 M 89.42 M — —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 0.0 0.0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 118.36 M 157.53 M 151.66 M 234.83 M 266.78 M
Total Liabilities 43.95 M 11.83 M 14.20 M 7.30 M 12.87 M
Shareholders' Equity 74.40 M 145.70 M 137.47 M 227.54 M 253.92 M
Total Debt — — — — —
Cash & Equivalents 95.50 M 128.57 M 121.14 M 201.02 M 233.44 M
Current Assets 97.71 M 136.53 M 129.63 M 211.23 M 244.48 M
Current Liabilities 43.83 M 11.75 M 14.20 M 7.06 M 12.53 M